ArticleVeterinary research communications2026
Activities of fungal metabolites sphaeropsidin A and B to fight against canine coronavirus.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pimarane diterpenes represent a notable class of metabolites. Secondary metabolites sphaeropsidin A (SphA) and sphaeropsidin B (SphB), produced by phytopathogenic fungi, have been recently reported for their potential efficacy against bovine coronavirus (BCoV). Hence, for discovering natural antivirals to serve as alternatives to conventional drugs, in this study the efficacy of SphA and SphB during infection with canine coronavirus (CCoV-II) in A72 cell line was examined. Our results demonstrated that a significant reduction in virus yield and in gene and protein expression of viral nucleocapsid protein (NP) was detected in sphaeropsidins (Sphs)-treated infected cells. In infected groups both Sphs enhanced cell viability and improved cellular morphology as well as cytoskeleton rearrangements. Moreover, the protein expression of aryl hydrocarbon receptor (AhR), a strategic modulator of CoVs infection, and of its target CYP1A1, was markedly downregulated in the presence of SphA and SphB during infection. These results were accompanied by a beneficial deacidification of lysosomal environment in infected cells treated with SphA and SphB compared to untreated-infected groups. Overall, our findings demonstrated a promising action of SphA and SphB towards CCoV infection in vitro.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.